Commercial Impact
We work with Tech Launch Arizona to commercialize discoveries and foster critical connections that acacceleratecelerates the commercialization of new technologies, diagnostics, and treatments. To see a full list of startups at the University of Arizona, visit the TechLaunch Startup Portfolio.
See active companies with current BIO5 members as of January 2023.
Photobioreactors used to produce various cell cultures including algae, cyanobacteria, fungi, bacteria, viruses, plant cells or tissues. The bioreactor has advantages over current technology by offering a low-cost and high-volume production mechanism for microorganism growth.
Aqualung Therapeutics (Aqualung Therapeutics Corporation) consists of a coalition of academic leaders, entrepreneurs, and translational scientists with expertise in precision medicine, exploring NAMPT as a key target and novel diagnostic in acute and chronic lung inflammatory disorders.
Auxilium Technology Group aims at maximizing value from waste streams while minimizing the environmental footprint of the mining industry. Our company has a unique value proposition, which is centered around the ability to offer complete solutions for tailings repurposing using our proprietary cutting-edge technologies.
Avery Therapeutics is a start-up company dedicated to advancing tissue-engineered therapeutics to treat diseases and injuries to human muscle. Their lead product, MyCardia™, is a tissue engineered heart graft developed to treat heart failure and is currently in the pre-clinical developmental phase. This technology is positioned to be the world’s first off-the-shelf allogenic tissue-engineered product for treating heart failure.
BG Networks’ vision is to enable IoT security everywhere. With our Security Automation Tools, we aim to remove obstacles that prevent embedded engineers from including cybersecurity in their applications.
At Clade Therapeutics, we’re shifting the paradigm of cell medicine by establishing a robust cellular platform with stem-cell derived immune cells for treatment of cancer and autoimmune diseases. Clade is a leading innovator in developing engineerable, off-the-shelf, scalable, and consistent cell medicines.
CLEAN EARTH TECH is an eco-friendly company that researches and develops technologies to clean earth’s atmosphere through fine dust and ultra-fine dust reduction technology. We always do our best to clean the environment and quality of life with the best products.
Codelucida empowers the future of storage with enhanced speed, reliability, and lower power usage. Codelucida develops software that enables flash-memory-based devices to have higher capacities, higher reliability, and faster speeds using less power at lower costs. These ultimately improve the efficiency and reliability of data centers, servers, and mission-critical storage that incorporate flash memories.
RapidBio Systems has developed a unique method for the rapid detection of food borne pathogens. The patented field portable technology economically detects organisms such as E. coli, Salmonella, Listeria, and many others.
ElectroSonix, LLC, is a medical device company that brings acoustoelectric, image-guided ultrasound therapy to market. By imaging real-time electrical currents in the body with their technologies, the company aims to improve diagnostic imaging and guided treatments for the heart and brain.
EVPSenors is developing sensing technology for non-invasive measurement of intraocular pressure (IOP). Elevated IOP is associated with glaucoma, an eye disease that if left untreated can lead to blindness.
A new high temperature ceramic material that uses graphene to strengthen its properties for use in extreme environments and a new method of joining complex ceramic components without the use of any intermediate joining material.
Fibronox, LLC, was founded to develop a small molecule inhibitor to treat life-threatening scarring and license the technology to bring it to the public. Their research has led to the first highly selective Nox4 small molecule inhibitors for the treatment of fibrotic diseases through the reduction of oxidative stress.
GenetiRate - Generating better Genetics in aquaculture species. Using UA patented technology GenetiRate selects fish and shellfish that grow more quickly and have improved feed efficiency.
GlycoSurf has a proprietary technology that produces high-purity and high-performance glycolipids for incorporation into cosmeceutical and personal-care products such as moisturizers, anti-oxidants, skin-lightening creams, anti-aging creams, and sunscreens.
i-calQ has developed the world’s first smartphone-based point-of-care integrated mobile diagnosis and decision support system. Using a drop of blood or saliva, a test can be performed, and the results interpreted anywhere and anytime. This technology does not require costly equipment or laboratory personnel. Accurate results, clinical interpretation, and recommendations for additional workup or treatment are delivered within minutes at a fraction of the cost of a comparable laboratory test and physician evaluation.
Illuminos Therapeutics has developed a series of novel small molecules for the treatment of Alzheimer’s disease and other neurodegenerative and cognitive diseases.
Innovative Energetics develops new materials and device technologies to produce next-generation batteries, optical materials, and optoelectronic materials while using sulfur-based materials for fuel cells.
LivEndocrine is developing new pharmaceutical treatments for Type II diabetes.
LUM.AI focuses on mitigating the innovation slowdown caused by information overload. The company applies natural language processing (NLP) technology to augment R&D investments by distilling libraries of unstructured text and revealing mechanisms that matter.
Luxxon Therapeutics is developing light-based therapies for chronic pain.
MAGPI is introducing a new technology for brain imaging. Its purpose is to improve the precision and robustness of brain phase images by combining multiple measurements obtained from different methods and channels. Some advantages include high-resolution images and more accurate results from a single scan.
MeCo Diagnostics is developing a "Mechanical Conditioning" Multi-Gene score for prediction and intervention of breast cancer bone metastasis. The MeCo Score is a candidate complementary diagnostic that identifies early-stage breast cancer patients at high risk for bone metastasis caused by mechanical conditioning, and it provides the rationale to intervene using low-toxicity, FDA-approved antifibrotics for "mechanical deconditioning therapy."
Module therapeutics is commercializing cell therapies using novel engineered receptors, known as 5MCARs, to precisely target and eliminate disease-causing T cells. Elimination of these pathogenic cells will elicit durable therapeutic benefits for patients suffering from autoimmune diseases.
The Mouse Cubby™ is an award-winning technology that significantly reduces aggression in laboratory mice and improves welfare, minimizing separation and euthanasia.
NEUTherapeutics aims to bridge discovery to cure through the development of regenerative treatments for neurodegenerative diseases and precision therapies that preserve women’s brain health.
PARMedics, Inc. is developing PAR inhibitors as therapeutics for pain and asthma.
PhytoCentric Solutions provides testing services to the food industry and has developed proprietary natural antimicrobial products for consumer applications.
Precision Epigenomics is an innovative molecular diagnostic testing service focused on superior diagnosis for better management and treatment of cancer patients.
Procyon Technologies develops and commercializes cellular therapies, in vivo analyte measurement, and drug delivery using oxygen-enabled implantable medical devices, with a special focus on diabetes.
ProNeurogen Inc. aims to develop drug therapies for preventing and treating cognitive impairment and pain-caused inflammation. Specifically, projects focus on harnessing the natural power of peptides to treat to neuronal dysfunction, cognitive impairment, and memory loss.
RaeSedo is developing novel analogues of naturally occurring lung proteins for treatment in patients with asthma and other respiratory diseases.
Regenerix is developing therapies for neurodegenerative disorders utilizing next-generation RIPK1/RIPK3 inhibitors.
Gene abnormalities often result in the manufacture of too little or too much protein causing a myriad of life-threatening diseases, such as cancer. Reglagene's medicines target the protein production problem at the source, the gene, and gets it back to functioning properly.
Regulonix was founded to address the growing opioid epidemic. Their science approaches the issue of treating pain in an entirely new way that is targeted and highly selective, resulting in non-addictive solutions.
Resonance Pharma is a strategic partnership between lipid R&D powerhouse, Cayman Chemical Company, and world-class experts in personalized medicine. This alliance leverages six decades of combined experience in the areas of lipid chemistry, biochemistry, and genetics with an intense focus on the role of lipids in disease biology to discover, develop, and deliver innovative diagnostics and medicines. This approach will ultimately advance precision therapeutics to address some of the world's most pressing and devastating diseases.
SaiOx, Inc., brings the benefits of heliox - a breathing gas mixture of helium and oxygen - to those having trouble breathing through a small, portable respiratory assist device. Though it was originally designed for at-home use by asthma and chronic obstructive pulmonary disease patients, its device has been of particular benefit to COVID-19 patients.
Scintillation Nanotechnologies, LLC, is a company focusing on the development and manufacturing of composite nanomaterials for detecting radioisotopes in biochemical research and drug discovery applications.
Teleost Biopharmaceuticals helps people protect themselves from sun damage by stimulating melanin production in the body by a method not triggered by the sun’s UV rays. The product will virtually eliminate the need for spray tans and tanning booths that increase cancer risk.
Endogenous neurotransmitters provide the starting point for Teleport Pharmaceuticals’' glycopeptide drugs for the treatment of degenerative neurological diseases. We are targeting neurogenerative diseases such as Alzheimer’s, Parkinson’s, and ALS or Lou Gehrig’s disease, as well as AIDS-related neuropathy, diabetic neuropathy, autism, stroke, and closed head injury. Teleport Pharmaceuticals is dedicated to novel peptide-based drug design for future therapeutics.
uPetsia helps pet owners solve the problem of bad dog breath. Their technology is incorporated into dog treats and chews and provides long lasting fresh breath with a mint aroma.
Valley Fever Solutions, Inc. (VFS) is moving Nikkomycin Z (NikZ) to the market as a therapy and potential cure for Valley Fever. VFS is studying pharmaceutical compounds and improved methods of diagnosing cocci and vaccine candidates intended for the prevention of valley fever.
Yumanity is dedicated to protecting the vitality of the mind. They are working to identify and develop new, disease-modifying therapies for Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis (ALS).
Partner with BIO5
Want to learn more about what BIO5 can offer industry partners? Schedule a tour, see our upcoming events, and donate to our programs.